Evidence map›Paper›PMID 30852371›Full record

ArticleInternational journal of surgery case reports2019

Secretory carcinoma of the breast: A case report.

Kamil Pohlodek, Iveta Mečiarová, Petr Grossmann, Petr Martínek, Zdeněk Kinkor

Open access · goldAbstract read
In one paragraph

Article in International journal of surgery case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools.Virchows Archiv : an international journal of pathology · 2024
    Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Kamil Pohlodek2nd Department of Gynecology and Obstetrics, Faculty of Medicine, Comenius University of Bratislava, Slovakia. Electronic address: kamil.pohlodek@fmed.uniba.sk.
Iveta MečiarováAlpha Medical Pathology Ltd., Bratislava, Slovakia.
Petr GrossmannDepartment of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Czech Republic; Bioptic Laboratory, Ltd., Plzen, Czech Republic.
Petr MartínekBioptic Laboratory, Ltd., Plzen, Czech Republic.
Zdeněk KinkorDepartment of Pathology, Charles University in Prague, Faculty of Medicine in Plzen, Czech Republic; Bioptic Laboratory, Ltd., Plzen, Czech Republic.
Biopticka Laborator (Czechia) · CZAlpha Medical (Slovakia) · SKCharles University · CZComenius University Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSecretory breast carcinoma (SBC) is a rare breast tumor which accounts for < 0.15% of all breast cancers. It was originally described as a juvenile breast carcinoma, occurring in young children and adolescent women. SBC is associated with a characteristic balanced translocation, t(12;15), that creates aETV6-NTRK3 gene fusion. PRESENTATION OF CASE: A 52-year-old Caucasian woman had palpable lump in her right breast. After breast imaging examination (BI-RADS 4b) and preoperative core-needle biopsy with suspicion of SBC a breast conserving therapy was performed. The diagnosis of SBC was confirmed through immunohistochemistry and cytogenetic examination of the tumor. The patient is now 22 months post‑surgery and remains disease‑free. DISCUSSION: Recent studies reported that the disease occurs at a later age than previously recognized, and is associated with good long-term survival. In breast imaging it may mimic a benign tumor. Immunohistochemistry and cytogenetic analysis of the tumor are crucial for confirmation of SBC.

conclusionThere is no consensus with regard to the best treatment strategy for patients with SBC. Breast conserving therapy with sentinel lymph nodes biopsy is at present the first choice treatment. Further research for a specific NTRK3 tyrosine kinase inhibitor could lead to the discovery of a new targeted treatment of this tumor.

Indexed as

Breast cancerBreast imagingBreast surgeryCase reportFluorescence in situ hybridizationImmunohistochemistrySectretory carcinoma

Identifiers

PMID30852371
PMCPMC6407075
OpenAlexW2920176180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.